Prostate cancer biomarker
View Patent ↗The present invention relates to the field of prostate cancer. Particularly the invention relates to villin as a novel prostate biomarker. The invention further relates to compositions comprising anti-villin antibodies and use of these compositions for an improved detection of prostate cancer in a subject.
1. A method of immunohistochemical characterization of solid tissue samples of prostate, comprising one or more prostate tumor cells, comprising:
(i) providing a sample obtained from the solid tissue of prostate obtained from a subject;
(ii) contacting the sample with a monoclonal anti-villin antibody;
(iii) detecting in the sample, the one or more prostate tumor cells comprising the anti-villin antibody bound to villin protein; and
(iv) immunohistochemically characterizing the sample, wherein the anti-villin antibody binds to villin protein expressed in the prostate tumor cells.
2. The method of claim 1 , wherein the method further comprises detecting the bound villin antibody.
3. The method of claim 1 , wherein the sample is a biopsy specimen.
4. The method of claim 1 , further comprising contacting the sample with one or more additional antibodies which bind to one or more of prostate specific antigen (PSA), prostate specific acid phosphatase (PSAP), p63, alpha-methylacyl-coenzyme-A racemase (AMACR), P504 S, cytokeratin 5/6 (CK5/6), high-molecular-weight cytokeratin 34 beta E12 (34 bE-12),chromogranin, CDX-2, cytokeratin 7 (CK7), and cytokeratin 20 (CK20).
5. The method of claim 4 , wherein the one or more additional antibodies bind to one or more of PSA, PSAP, and AMACR.
6. The method of claim 5 , further comprising contacting the sample with an antibody which binds to CDX-2.